MMR IHC Panel pharmDx (Dako Omnis)
Agilent Technologies, Inc. · Decision date Aug 15, 2025
What did the FDA approve?
FDA records P250004 as an original PMA application. The recorded decision is approval, dated Aug 15, 2025.
FDA approval order statement
For In Vitro Diagnostic Use.MMR IHC Panel pharmDx (Dako Omnis) is a qualitative immunohistochemical (IHC) assay intended for use in the assessment of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2, and MSH6) in formalin-fixed, paraffin-embedded (FFPE) colorectal cancer (CRC) tissue using EnVision FLEX visualization system on Dako Omnis automated staining instrument. MMR IHC Panel pharmDx (Dako Omnis) consists of MLH1 IHC pharmDx (Dako Omnis), PMS2 IHC pharmDx (Dako Omnis), MSH2 IHC pharmDx (Dako Omnis), and MSH6 IHC pharmDx (Dako Omnis), which must be used together to identify MMR deficient CRC patients.MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify MMR deficient CRC patients eligible for treatment with OPDIVO (nivolumab) alone or OPDIVO (nivolumab) in combination with YERVOY (ipilimumab).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Aug 15, 2025
Regulatory record facts
- Identifier
- P250004
- Regulatory pathway
- Premarket approval application
- Applicant
- Agilent Technologies, Inc.
- Product code
- QNH
- Decision code
- APPR
- Decision date
- Aug 15, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay.
- Applicant
- Agilent Technologies, Inc.
- Product code
- QNH
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250004 received
Application receipt date recorded by FDA.
P250004 · FDA decision
APPR
P250004/S001 · Related supplement
MMR IHC Panel pharmDx (Dako Omnis)
Timeline entries are records held by MedtechLedger for P250004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MMR IHC Panel pharmDx (Dako Omnis)P250004/S001 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
Explore the linked device profile
Other records with product code QNH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VENTANA MMR RxDx PanelP200019/S014 | Ventana Medical Systems | PMA supplement | Oct 8, 2026 | FDA |
VENTANA MMR RxDx PanelP210001/S016 | Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) | PMA supplement | Oct 8, 2026 | FDA |
VENTANA MMR RxDx PanelP210001 | Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) | PMA approval | Aug 17, 2021 | FDA |
VENTANA MMR RxDx PanelP200019 | Ventana Medical Systems | PMA approval | Apr 22, 2021 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6392 Via Real, Carpinteria, CA, 93013
Sources and methodology
- Original FDA record: P250004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

